louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02381912: Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer
Official title: Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Urinary Bladder Neoplasms
Sexual Dysfunction, Physiological
Sexual Dysfunctions, Psychological
Erectile Dysfunction
Hematuria
Lead sponsor: Herlev Hospital
Sponsor class: OTHER
First posted: 2015-03-06
Enrollment: 210
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with primary hematuria.

Brief summary: The purpose of the study is to investigate sexual function in patients suspected of non muscle invasive bladder cancer (NMIBC). The investigators hypothesis is that reduced sexual function is underdiagnosed in patients with non-muscle invasive bladder cancer and that active examination and treatment may worsen the sexual function.


Eligibility criteria: Inclusion Criteria:

* Patients with primary hematuria, both gross and microscopic
* Men and women older or equal to 40 years of age
* Signed informed consent statement

Exclusion Criteria:

* Men and women younger than 40 years of age
* Patients with recurrent hematuria and known causative disease
* Already known urogenital cancer
* Previous massive pelvic surgery or pelvic radiotherapy
* TUR-P within the last 2 months
* Participants diagnosed with tumors originating from the ureters, renal pelvis and kidney, and bladder tumors at T stage more than or equal to T1b.

Primary outcomes:
measure: Change in sexual function
timeFrame: 4 months
Secondary outcomes:
measure: Change in erectile function
timeFrame: 4 months
Other outcomes:
Locations:
city: Herlev
country: Denmark
facility: Herlev Hospital
Study officials:
affiliation: Herlev Hospital, Department of Urology
name: Peter B Østergren, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kowalkowski MA, Chandrashekar A, Amiel GE, Lerner SP, Wittmann DA, Latini DM, Goltz HH. Examining sexual dysfunction in non-muscle-invasive bladder cancer: results of cross-sectional mixed-methods research. Sex Med. 2014 Aug;2(3):141-51. doi: 10.1002/sm2.24.
citation: van der Aa MN, Bekker MD, van der Kwast TH, Essink-Bot ML, Steyerberg EW, Zwarthoff EC, Sen FE, Elzevier HW. Sexual function of patients under surveillance for bladder cancer. BJU Int. 2009 Jul;104(1):35-40. doi: 10.1111/j.1464-410X.2008.08333.x. Epub 2009 Jan 14.
citation: Goossens-Laan CA, Kil PJ, Ruud Bosch JL, De Vries J. Pre-diagnosis quality of life (QoL) in patients with hematuria: comparison of bladder cancer with other causes. Qual Life Res. 2013 Mar;22(2):309-15. doi: 10.1007/s11136-012-0163-1. Epub 2012 Mar 30.
Clinical trial NCT06835712: Virtual Reality and Guided Imagery to Reduce Procedural Pain
Official title: Virtual Reality and Guided Imagery to Reduce Pain During Peripheral Intravenous Catheterization Procedure in Adults: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain Management
Virtual Reality Pain Distraction
Guided Imagery
Peripheral Intravenous Catheterization Application
Keywords: virtual reality
guided imagery
pain management
peripheral intravenous catheterization
Lead sponsor: Izmir Katip Celebi University
Sponsor class: OTHER
First posted: 2025-02-19
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Aim: The aim of the present study was to examine the effect of virtual reality and guided imagery to reduce pain during peripheral intravenous catheterization procedures in adults.Methods: The study will include 90 adults who were randomly selected between February and March 2025. One application group (n=30) will receive a virtual reality glasses application; the other application group (n=30) will receive a guided imagery application. The applications to the site of the peripheral intravenous catheterization will last two minutes. The control group (n=30) will receive the standard peripheral intravenous catheterization application procedure. The groups' level of pain during catheterization will be assessed using a visual analog scale.


Eligibility criteria: Inclusion Criteria:

* Being in accordance with time and place
* Being in no sensory problems
* Being aged between 18 and 65 years
* Being able to evaluate the visual analog scale correctly
* Participating voluntarily in the research.

Exclusion Criteria:

* Not participating voluntarily in the research
* Not fitting the inclusion criteria of the research
* Having a vision or hearing problem
* Having any illness which could affect pain perception, such as sensorymotor disorder, diabetes, peripheral vascular diseases or peripheral neuropathy
* Having phlebitis, scar tissue, dermatitis, an incision or findings of infection at the place where the intervention was to be performed
* Having taken an analgesic (within the previous six hours) or an anesthetic agent before the peripheral intravenous catheterization procedure

Primary outcomes:
measure: procedure duration in sec
timeFrame: during the intervention/procedure
measure: pain intensity in mm
timeFrame: during the intervention/procedure
measure: procedure satisfaction in mm
timeFrame: during the intervention/procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Izmir
country: Turkey
facility: Izmir Katip Celebi University
state: Cigli
Study officials:
References:
Clinical trial NCT00988312: Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
Official title: Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Multiple Myeloma
Plasmocytoma
Keywords: dendritic cells (DC)
idiotype (Id)
immunotherapy
Lead sponsor: University Hospital Carl Gustav Carus
Sponsor class: OTHER
First posted: 2009-10-02
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.


Eligibility criteria: Inclusion Criteria:

* multiple myeloma
* stage I (Salmon \& Durie)
* no cytoreductive pre-treatment

Exclusion Criteria:

* myeloma stages II-III
* asecretory disease

Primary outcomes:
measure: Specific T-cell proliferation/cytokine secretion
Secondary outcomes:
measure: number of T cells
timeFrame: pre and post vaccination
measure: monoclonal protein
timeFrame: pre and post vaccination
measure: plasmacells in bone marrow
timeFrame: pre and post vaccination
measure: vital signs
timeFrame: pre and post vaccination
Other outcomes:
Locations:
city: Dresden
country: Germany
facility: University Hospital Dresden
Study officials:
affiliation: University Hospital Dresden
name: Susanne Gretzinger, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05585112: Articaine 4% Versus Lidocaine 2% for Local Anesthesia of MIH-affected Maxillary Molars
Official title: Comparative Study of Articaine 4% Versus Lidocaine 2% in Local Anesthesia and Permanent Maxillary First Molars Affected by MIH.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Molar Incisor Hypomineralisation
Keywords: local anesthesia
Lidocaine 2%
Articaine 4%
molars
Lead sponsor: Tishreen University
Sponsor class: OTHER
First posted: 2022-10-18
Enrollment: 26
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: A randomized, controlled, crossover, Triple-blinding clinical study, Comparison of articaine 4% and lidocaine 2%
Primary purpose: TREATMENT

Brief summary: Comparison of injection pain with lidocaine and articaine. Comparison of the efficacy of lidocaine and articaine during treatment of MIH- maxillary molars.

Design: A randomized, controlled, crossover, Triple-blinding clinical study including twenty six cooperative children, aged 6-12years old

Detailed description: Background and Aims: Some dentists have difficulty obtaining effective anesthesia when treating MIH molars.

There are no studies comparing the effectiveness of lidocaine and articaine in MIH-maxillary molars.

Design: A randomized, controlled, crossover, Triple-blinding clinical study including twenty six cooperative children , aged 6-12 years old. Each child was randomly assigned to either articaine 4% or lidocaine 2% in their first session with the second solution being used at the second session.

Eligibility criteria: Inclusion Criteria:

* Absolute positive or positive behavior according to the Frankel Scale.
* child is not under the effect of any analgesics or sedatives and their weight was more than 20 kg.
* Healthy, both physically and mentally
* A child with a MIH-affected maxillary permanent first molar on the right and left sides .

Exclusion Criteria:

* children who are uncooperative
* allergic anesthetics used in the study
* children who show inflammation in the injection site.

Primary outcomes:
measure: injection pain
timeFrame: during the injection of local anesthesia procedure
measure: injection pain
timeFrame: Immediately after the injection of local anesthesia procedure
measure: dental pain
timeFrame: during procedure
measure: dental pain
timeFrame: Immediately after treatment procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Latakia
country: Syrian Arab Republic
facility: Tishreen University
Study officials:
affiliation: Tishreen University
name: Nabih Raslan, Dr
role: STUDY_CHAIR
affiliation: Tishreen University
name: Mai Haidar, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01185912: Cardiomyocyte Apoptosis Following Antegrade and Retrograde Cardioplegia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiomyocyte Apoptosis
Keywords: Cardiac MRI
Cardiac ultrasound
Cardiac surgery
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Finnish Foundation for Cardiovascular Research
First posted: 2010-08-20
Enrollment: 20
Sex: ALL
Minimum age (years): 60
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 20 patients (male and female) undergoing elective aortic valve replacement surgery due to aortic valve stenosis or combined aortic valve disease in Turku University Hospital, Department of Surgery.

Brief summary: Retrograde cardioplegia during heart surgery is associated with inadequate myocardial protection. In experimental animal study retrograde cardioplegia induces more cardiomyocyte apoptosis when compared to antegrade cardioplegia. 20 volunteer patients under going elective aortic valve surgery will be divided in to two groups: 10 patients receiving only antegrade cardioplegia and 10 patients receiving only retrograde cardioplegia. Pre- and post-operatively cardiac MRI and cardiac ultrasound will be performed. During the surgery ventricular muscle samples will be taken in order to assess cardiomyocyte apoptosis. Aims of the study: 1. whether the cardiomyocyte apoptosis is significantly more induced after retrograde cardioplegia than antegrade cardioplegia, 2. whether the amount of apoptotic cardiomyocytes correlates to conventional markers of myocardial injury after cardiac surgery, 3. whether the extent of irreversible myocardial damage by apoptosis correlates to post-ischemic contractile dysfunction after cardiac surgery, as measured with echocardiography, 4. whether the amount of cardiomyocyte apoptosis correlates to long term outcome and cardiac function as measured with MRI.


Eligibility criteria: Inclusion Criteria:

* aortic valve stenosis or combined aortic valve disease

Exclusion Criteria:

* angiographically verified hemodynamically significant coronary artery disease impaired left ventricular function (left ventricular ejection fraction \<50%) surgery including additional procedures other than aortic valve replacement cancer

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Turku
country: Finland
facility: Turku University Hospital, Department of Surgery
Study officials:
References:
Clinical trial NCT00322712: INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer
Official title: INST 0603C Chart Review on Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Pancreatic Cancer
Lead sponsor: University of New Mexico
Sponsor class: OTHER
First posted: 2006-05-08
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.

Brief summary: Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.

Detailed description: Chart Review to describe the clinical outcomes in patients pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.

Eligibility criteria: Inclusion Criteria:

Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.

Exclusion Criteria:

Not specified.

Primary outcomes:
measure: Time to Death
timeFrame: From date of treatment until time of death
Secondary outcomes:
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: University of New Mexico
state: New Mexico
Study officials:
affiliation: University of New Mexico
name: Fa-Chyi Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01747512: An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)
Official title: A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Thyroid Neoplasms
Head and Neck Neoplasms
Keywords: 99mTc Pertechnetate
thyroidectomy
thyroid neoplasms
Lead sponsor: AHS Cancer Control Alberta
Sponsor class: OTHER
Collaborators: name: Cross Cancer Institute
First posted: 2012-12-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Doctors at the Cross Cancer Institute have developed a new method of producing 99mTc Pertechnetate in a cyclotron unit. A study done at the Cross Cancer Institute in 2011 with ten patients using this imaging agent showed that it was safe and produced images with the same pattern as generator produced Pertechnetate. This study is now being done in larger numbers of patients to again show that the imaging pattern of both agents is the same, and to again demonstrate its safety.

Detailed description: To demonstrate the efficacy of cyclotron-produced Tc-99m pertechnetate (C-PERT; manufactured by the Edmonton PET Centre/ERC) in comparison to generator-produced Tc-99m pertechnetate (G-PERT; from approved commercial source; using qualitative and quantitative clinical imaging biodistribution data.

Eligibility criteria: Inclusion Criteria:

* thyroid cancer, or
* Head and Neck cancer for salivary gland transfer
* age 18-79
* biochemical parameters \< 5x ULN
* WBC \> 3.0/uL
* ANC \> 1.5/uL
* platelets \> 75,000/uL
* hemoglobin \> 10 g/dL
* Karnofsky 50-100

Exclusion Criteria:

* nursing or pregnant females
* \< 18 or \> 79 Years
* uncontrolled asthma
* acute iritis
* narrow angle glaucoma
* previous radiation to head/neck

Primary outcomes:
measure: To demonstrate the efficacy of C-PERT (manufactured by the Edmonton PET Centre/ERC) in comparison to G-PERT (fromm approved commercial sources) using qualitative and quantitative clinical imaging biodistribtion data.
timeFrame: 5 months
Secondary outcomes:
measure: To evaluate the safety of C-PERT from adverse event data
timeFrame: 5 months
Other outcomes:
Locations:
Study officials:
affiliation: Professor, Department of Oncology
name: Alexander McEwan, MB, FRCPC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00651612: Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Glaucoma
Ocular Hypertension
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2008-04-03
Enrollment: 604
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients


Eligibility criteria: Inclusion Criteria:

* Diagnosis of ocular hypertension or glaucoma
* Patient requires IOP-lowering therapy in both eyes

Exclusion Criteria:

* Uncontrolled medical conditions
* Contraindication to β-adrenoceptor antagonist therapy or brimonidine therapy

Primary outcomes:
measure: Adverse Events
timeFrame: Day 10
Secondary outcomes:
Other outcomes:
Locations:
city: Newport Beach
country: United States
state: California
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT02196012: A Technology-Based Intervention for the Reduction of Overweight and Obesity Among College Students
Official title: "The UTK Health Study" A Technology-Based Weight Loss Intervention for the Reduction of Overweight and Obesity Among College Students."
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overweight and Obesity
Keywords: overweight
obesity
Technology
College Students
Lead sponsor: The University of Tennessee, Knoxville
Sponsor class: OTHER
First posted: 2014-07-21
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 22
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the feasibility and acceptability and efficacy of a two month technology-based weight loss program for overweight and obese college students.

Detailed description: A randomized controlled trial design will be employed to investigate the effectiveness, feasibility, and acceptability of a technology-based weight loss pilot intervention for the reduction of overweight and obesity in college students. Participants will be randomly assigned to one of two conditions: (1) 8-week intervention group, or (2) 8-week attention control group. Both conditions include 8 weekly lessons over 8 weeks. Undergraduate students (n=100) age 18-22 years who are overweight or obese (BMI ≥ 25 kg/m2) will be recruited from the University of Tennessee Knoxville. Measurements will be taken at baseline and 8 weeks. Since the study is a technology-based intervention, research staff will collect height and weight measures for BMI through a novel approach, utilizing Skype video conferencing.

Eligibility criteria: Inclusion Criteria:

* Eligibility will include UTK undergraduate students who are overweight or obese (BMI ≥ 25 kg/m2) and between 18-22 years of age, with access to the Internet, a personal computer (laptop, tablet, or desktop computer), and a smartphone.

Exclusion Criteria:

* Any individual who does not meet all the inclusion criteria will be excluded from participation in the study.
* Students who have a medical condition that precludes adherence to dietary recommendations
* Who are currently prescribed medications that may impact weight, or who are currently participating in or planning to participate in another weight loss programs in the next six months
* Who have been diagnosed with a major psychiatric illness (e.g., bipolar disorder, schizophrenia, or depression) within the last 12 months
* Who are pregnant or plan to become pregnant in the next six months
* Who have given birth within the last six months
* Who have been diagnosed with any type of eating disorder within the past 12 months will be ineligible.

Primary outcomes:
measure: body mass index (BMI)
timeFrame: 2 months
Secondary outcomes:
measure: feasibility
timeFrame: 2 months
Other outcomes:
measure: acceptability
timeFrame: 2 months
Locations:
city: Knoxville
country: United States
facility: University of Tennessee
state: Tennessee
Study officials:
References: